# RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias

- Link: https://www.thailand-business-news.com/pr-news/ribox-therapeutics-announces-fda-ind-clearance-for-rxim002-the-first-circular-rna-based-in-vivo-car-therapy-for-autoimmune-cytopenias
- Published: 2026-08-08T14:46:00+07:00
- Author: PR Newswire

_The FDA IND clearance supports the initiation of RiboX’s Phase 1 clinical trial
evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune
cytopenias._

_RXIM002 represents the world’s first circular RNA-based in vivo CAR-T therapy achieving
FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary
targeted LNP delivery platform._

SHANGHAI and CAMBRIDGE, Mass., Aug. 8, 2026 /PRNewswire/ — RiboX Therapeutics Ltd.("
RiboX"), a global clinical-stage biotechnology company pioneering fully engineered
circular RNA (circRNA) therapeutics, announced today that the U.S. Food and Drug
Administration (FDA) has cleared the company’s Investigational New Drug (IND) application
for RXIM002. RXIM002 is the world’s first circular RNA-based _in vivo_ CAR-T therapy
delivered by a targeted lipid nanoparticle (tLNP). This marks an important milestone
for the field as circRNA-based _in vivo_ CAR-T officially advancing into clinical
development.

RXIM002 is an investigational product employing tLNP encapsulated circRNA that encodes
a CD19‑targeting chimeric antigen receptor (CAR) for the treatment of autoimmune
cytopenias. By delivering circRNA to T cells _in vivo_, RXIM002 enables durable 
CAR expression and generating functional CAR-T cells directly within the patient’s
body. This "in situ generation" approach fundamentally bypasses the complex, costly
and time-consuming _ex vivo_ manufacturing processes required by conventional CAR-
T therapies, expanding patient access. In autoimmune diseases, deep B cell depletion
driven by the _in vivo _generated CAR-T cells has the potential to induce immune
reset and durable drug-free remission.

Prior to the IND submission, RXIM002 was evaluated in investigator-initiated trials(
IITs) in China in autoimmune disease patients. Follow-up of these patients are currently
ongoing, with some patients exceeding six months. RiboX submitted complete IIT data
as part of the IND package to the FDA, encompassing safety and early efficacy results
from all treated patients. Based on the integrity and robustness of this full dataset,
the agency permitted an accelerated dose-titration scheme and granted subcutaneous
formulation as part of clinical development, paving the way for potentially outpatient
administration that could fundamentally transform the CAR-T treatment paradigm.

To the company’s knowledge, RXIM002 is the world’s first tLNP-circRNA _in vivo_ 
CAR therapy that achieved FDA IND clearance. This milestone validates RiboX’s proprietary
tLNP platform and further reinforces the company’s leadership in precision RNA therapeutics.

"The FDA IND clearance for RXIM002 is a pivotal milestone for RiboX and for the 
field of circRNA medicines," said Weiyi Zhang, Ph.D., Chief Executive Officer of
RiboX Therapeutics. "As the first-in-class circRNA _in vivo_ CAR-T therapy to enter
the clinic, RXIM002 exemplifies our ability to translate robust pre-clinical results
and rigorous early clinical evidence into an accelerated development path. This 
achievement brings us closer to delivering a transformative treatment option for
patients living with debilitating autoimmune diseases. We are committed to advancing
clinical research of RXIM002 across multiple regions worldwide to address the significant
unmet needs."

**About RXIM002**

RXIM002 is a first-in-class, tLNP-delivered circRNA therapy encoding an anti-CD19
CAR. It’s designed to generate functional CAR T cells in vivo to achieve durable,
non-integrating CAR-expression. By inducing profound depletion of pathogenic B cells,
RXIM002 promotes immune reset and sustained disease remission, offering a potentially
transformative, off-the-shelf solution for patients with B-cell-driven autoimmune
diseases.

**About POPULUS-1 Study**

POPULUS-1 is a Phase 1 clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics,
and early efficacy of RXIM002 in patients with relapsed or refractory autoimmune
cytopenias. The study will initially enroll participants with relapsed or refractory
immune thrombocytopenia (ITP), the most prevalent autoimmune cytopenia, characterized
by a low platelet count and an increased risk of bruising and bleeding. ITP is caused
by pathogenic autoantibodies driven by aberrant B-cell activation. RXIM002 is being
developed to induce transient _in vivo_ CAR T-cell mediated depletion of pathogenic
B cells while potentially preserving immune competence.

**About RiboX Therapeutics**

RiboX Therapeutics is a global, clinical-stage biotechnology company dedicated to
discovering and developing circRNA therapeutics with operations in China, US and
Israel. RiboX develops proprietary circRNA and targeted LNP platforms that enable
durable expression, precision tissue targeting and broad therapeutic applicability
across multiple disease areas.

**Forward-Looking Statements**

This press release contains forward-looking statements regarding the development,
regulatory advancement, clinical evaluation, safety, efficacy, and commercial potential
of RXIM002 and the Company’s circular RNA and targeted lipid nanoparticle platforms.
Actual results may differ materially due to various risks and uncertainties. RiboX
undertakes no obligation to update forward-looking statements except as required
by law.

**For Further Information, please visit: **[http://www.riboxtx.com/](http://www.riboxtx.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias ](http://www.prnasia.com/story/archive/5022222_CN22222_0?rand=184833)
